CWIG
PVLA

Chung Wu Investment Group’s Palvella Therapeutics PVLA Stock Holding History

Chung Wu Investment Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$168K Sell
1,100
-1,200
-52% -$146K 0.11% 114
2026
Q1 		$287K Sell
2,300
-300
-12% -$31.3K 0.25% 69
2025
Q4 		$272K Buy
2,600
+2,400
+1,200% +$205K 0.22% 73
2025
Q3 		$12.5K Buy
+200
New +$8.92K 0.01% 199

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Chung Wu Investment Group's PVLA Position: Q2 2026 in Review

Chung Wu Investment Group reduced its Palvella Therapeutics (PVLA) stake by 52% in Q2 2026, selling an estimated $146K and leaving 1,100 shares worth $168K. The position accounts for 0.11% of the portfolio, ranked #114.

Chung Wu Investment Group first reported a position in PVLA in Q3 2025 and has held it in 4 quarters since. The position peaked at $287K in Q1 2026. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Chung Wu Investment Group held 1,100 shares of Palvella Therapeutics worth $168K as of Q2 2026.
  • Chung Wu Investment Group sold 1,200 Palvella Therapeutics shares in Q2 2026, an estimated $146K.
  • Palvella Therapeutics made up 0.11% of Chung Wu Investment Group's portfolio in Q2 2026, its #114 holding.
  • Chung Wu Investment Group first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Chung Wu Investment Group's Palvella Therapeutics position peaked at $287K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Chung Wu Investment Group's 13F filing for Q2 2026, filed 31 Jul 2026.